Triple
T19772732
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Array BioPharma |
E474928
|
entity |
| Predicate | hasTherapy |
P73562
|
FINISHED |
| Object | BRAF inhibitor encorafenib |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: BRAF inhibitor encorafenib | Statement: [Array BioPharma, hasTherapy, BRAF inhibitor encorafenib]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: BRAF inhibitor encorafenib Context triple: [Array BioPharma, hasTherapy, BRAF inhibitor encorafenib]
-
A.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
B.
nivolumab
Nivolumab is a monoclonal antibody immunotherapy drug that blocks the PD-1 immune checkpoint to enhance the body’s anti-tumor response in various cancers.
-
C.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
D.
LOXO-305
LOXO-305 is a highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor being developed as a targeted therapy for B-cell malignancies such as chronic lymphocytic leukemia.
-
E.
Libtayo
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: BRAF inhibitor encorafenib Target entity description: BRAF inhibitor encorafenib is a targeted cancer therapy used primarily to treat tumors harboring specific BRAF mutations, such as certain forms of melanoma and colorectal cancer.
-
A.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
B.
nivolumab
Nivolumab is a monoclonal antibody immunotherapy drug that blocks the PD-1 immune checkpoint to enhance the body’s anti-tumor response in various cancers.
-
C.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
D.
LOXO-305
LOXO-305 is a highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor being developed as a targeted therapy for B-cell malignancies such as chronic lymphocytic leukemia.
-
E.
Libtayo
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8e51a43a08190956bc6df13c91a77 |
completed | April 10, 2026, 11:55 a.m. |
| NER | Named-entity recognition | batch_69e6535ce4d08190a1dfca2df95a8631 |
completed | April 20, 2026, 4:25 p.m. |
Created at: April 10, 2026, 1:48 p.m.